A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain
Active, not recruiting · Phase 3 · NCT07035093
Conditions: Obesity, Overweight, Chronic Low Back Pain (CLBP)
At a glance
- Research payments reported, 2025
- $5.7M
- U.S. investigators named
- 18
- Sites paid
- 17
- Planned or actual enrollment
- 586
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- Retatrutide (drug), Placebo (drug)
- Dates
- Started 2025-05-29; completion 2027-09
- Results posted
- Not yet
The main purpose of this study is to evaluate the efficacy and safety of retatrutide in relieving chronic low back pain in participants who have obesity or overweight. Participation in the study will last about 80 weeks.
From ClinicalTrials.gov, last updated 2026-09-25. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $5.7M in research payments for this study in 2025 (18 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Hemant K. Pandey, MD Neurology · Chandler, AZ
- Stacey L. Layle, MD Family Medicine · San Diego, CA
- Justin L. Yanuck, M.D. Emergency Medicine · Downey, CA
- Paul K. Brownstone, M.D. Clinical Pharmacology · Boulder, CO
- Howard N. Chipman III, M.D. Family Medicine · Oldsmar, FL
- Mark E. Kutner, MD Internal Medicine · Miami, FL
- Shital R. Mehta, D.O. Internal Medicine · Wesley Chapel, FL
- Esteban Olivera, MD Emergency Medicine · Kissimmee, FL
- Anand A. Patel, MD Pain Medicine · Ormond Beach, FL
- Natalie L. Clarke, MD Anesthesiology · Evans, GA
- Katherine J. Willingham, MD Internal Medicine · Topeka, KS
- William C. Nabours, MD Family Medicine · Lake Charles, LA
- David J. Dibenedetto, M.D. Pain Medicine · Waltham, MA
- Stephen M. Miller JR., M.D. General Surgery · Boston, MA
- Jeffrey A. Potts, MD Internal Medicine · Bay City, MI
- Ralph J. Duda JR., M.D. Endocrinology & Diabetes · Springfield, MO
- Alan Kivitz, MD Rheumatology · Duncansville, PA
- Ebere I. Azubuike, MD Family Medicine · Dallas, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Charter Research LLC $900,691
- New Phase Research & Development LLC $726,705
- Conquest Research LLC $661,995
- Great Lakes Research Group Inc $600,463
- Medvadis Research Corp LLC $426,030
- K2 Medical Research LLC $327,373
- Biopharma Informatic Inc $325,650
- Ark Clinical Research LLC $298,669
- Altoona Center for Clinical Research PC $245,665
- Mdfirst Research Chandler LLC $205,669
- Artemis Headlands LLC $192,797
- Care Access Research LLC $180,896
- Ima Evaluations LLC DBA Ima Clinical Research $169,378
- Clinvest Headlands LLC $132,557
- Alpine Clinical Research Center Inc $115,364
- Cotton Oneil Msd of Stormont Vail Healthcare $104,901
- Flourish Research Acquisition LLC $104,784
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.